A maior negociata do ano foi a "pandemia" do H1N1.In the short term, at least, H1N1 vaccine sales will give a major lift to sales at the three major European vaccine makers. GSK says analyst predictions for $1.7 billion of H1N1 vaccine sales in the fourth quarter are broadly accurate, and similar numbers are forecast for the first quarter 2010. Novartis says it expects $700 million in fourth-quarter sales alone of its H1N1 pandemic vaccine. And Sanofi-Aventis says it expects H1N1 sales in the fourth quarter to hit $500 million.
Via Spiegel
Sem comentários:
Enviar um comentário